# ITIL-306 in Advanced Solid Tumors

Source: https://onco.cc/trials/nct05397093/  
OnCo record `nct05397093` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ITIL-306 run by Instil Bio, terminated.

## Summary

ITIL-306 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT05397093 by Instil Bio, with 1 participants enrolled, started 2022-08-24. Conditions recorded: Epithelial Ovarian Cancer, Non-small Cell Lung Cancer and Renal Cell Carcinoma. Interventions recorded: ITIL-306.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05397093
- Phase: 1
- Setting: A Phase 1a/1b, Open-Label, Multicenter Study Evaluating the Safety and Feasibility of ITIL-306 in Subjects With Advanced Solid Tumors
- Sponsor: Instil Bio
- Enrolled: 1

## Sources

- ClinicalTrials.gov NCT05397093: https://clinicaltrials.gov/study/NCT05397093

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [ITIL-306](https://onco.cc/drugs/itil-306/)
- companies: [Instil Bio](https://onco.cc/companies/instil-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct05397093.json